Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study

被引：9
|
作者：
Overcast, Wynton B. [1 ]
Zhang, Jianying [2 ]
Zynger, Debra L. [3 ]
Tozbikian, Gary H. [3 ]
机构：
[1] Ohio State Univ, Coll Med, 410 W 10th Ave,E410 Doan Hall, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Biostat, 320 Lincoln Tower,1800 Cannon Dr, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Pathol, Wexner Med Ctr, 410 W 10th Ave,E410 Doan Hall, Columbus, OH 43210 USA
来源：
VIRCHOWS ARCHIV | 2016年 / 469卷 / 02期
关键词：
ASCO/CAP guidelines; Breast cancer; Equivocal category; HER2 immunohistochemistry (IHC); HER2 fluorescence in situ hybridization (FISH); IN-SITU HYBRIDIZATION; POLYMERASE CHAIN-REACTION; CLINICAL ONCOLOGY/COLLEGE; AMERICAN SOCIETY; COPY NUMBER; CANCER; RECEPTOR; IMMUNOHISTOCHEMISTRY; TRASTUZUMAB; FISH;
D O I：
10.1007/s00428-016-1951-8
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
[No abstract available]
引用
收藏
页码：203 / 212
页数：10
相关论文
共 50 条
  • [41] The Impact of 2013 ASCO/CAP Guidelines on the Practice of HER2 Testing in a Reference Laboratory
    Hanna, Wedad
    Slodkowska, Elzbieta
    Lu, Fang-I
    Han, Guangming
    Nafisi, Houman
    Nofech-Mozes, Sharon
    LABORATORY INVESTIGATION, 2016, 96 : 44A - 44A
  • [42] The Impact of 2013 ASCO/CAP Guidelines on the Practice of HER2 Testing in a Reference Laboratory
    Hanna, Wedad
    Slodkowska, Elzbieta
    Lu, Fang-I
    Han, Guangming
    Nafisi, Houman
    Nofech-Mozes, Sharon
    MODERN PATHOLOGY, 2016, 29 : 44A - 44A
  • [43] Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience
    Varga, Zsuzsanna
    Noske, Aurelia
    PLOS ONE, 2015, 10 (10):
  • [44] Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
    Bo Wang
    Wei Ding
    Ke Sun
    Xiaoling Wang
    Liming Xu
    Xiaodong Teng
    Scientific Reports, 9
  • [45] Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
    Wang, Bo
    Ding, Wei
    Sun, Ke
    Wang, Xiaoling
    Xu, Liming
    Teng, Xiaodong
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [46] The Impact of 2013 Updated ASCO/CAP HER2 Guidelines on the Diagnosis and Management of Invasive Breast Cancer: A Single-Center Study of 1739 Cases
    Zhang, Xiaofei
    Bleiweiss, Ira
    Jaffer, Shabnam
    Nayak, Anupma
    CLINICAL BREAST CANCER, 2017, 17 (06) : 486 - 492
  • [47] Increase of Equivocal In Situ Hybridization Results in 2013 ASCO/CAP Guidelines for HER2 Testing in Invasive Breast Cancer: Comparison With the 2007 Criteria
    Espinet, Blanca
    Maria Puiggros, Anna
    Maria Corominas, Josep
    Iglesias, Mar
    Rodriguez-Rivera, Maria
    Carme Melero, Maria
    Albanell, Joan
    Tusquets, Ignacio
    Servitja, Sonia
    Serrano, Sergio
    Salido, Marta
    LABORATORY INVESTIGATION, 2015, 95 : 43A - 43A
  • [48] Increase of Equivocal In Situ Hybridization Results in 2013 ASCO/CAP Guidelines for HER2 Testing in Invasive Breast Cancer: Comparison With the 2007 Criteria
    Espinet, Blanca
    Maria Puiggros, Anna
    Maria Corominas, Josep
    Iglesias, Mar
    Rodriguez-Rivera, Maria
    Carme Melero, Maria
    Albanell, Joan
    Tusquets, Ignacio
    Servitja, Sonia
    Serrano, Sergio
    Salido, Marta
    MODERN PATHOLOGY, 2015, 28 : 43A - 43A
  • [49] Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
    Lei Guo
    Pei Yuan
    Jing Zhang
    Yun Ling
    Wenbin Li
    Bohui Zhao
    Jianming Ying
    Lixue Xuan
    Breast Cancer Research and Treatment, 2017, 166 : 77 - 84
  • [50] Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
    Guo, Lei
    Yuan, Pei
    Zhang, Jing
    Ling, Yun
    Li, Wenbin
    Zhao, Bohui
    Ying, Jianming
    Xuan, Lixue
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 77 - 84
12345